Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo

Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). Here we investigated the reversal effect of alectinib on multidrug resistance (MDR) induced by ATP-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ke, Chen, Yifan, To, Kenneth Kin Wah, Wang, Fang, Li, Delan, Chen, Likun, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382559/
https://www.ncbi.nlm.nih.gov/pubmed/28303028
http://dx.doi.org/10.1038/emm.2016.168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382559/
https://www.ncbi.nlm.nih.gov/pubmed/28303028
http://dx.doi.org/10.1038/emm.2016.168

Ejemplares similares